Mainz Biomed (NASDAQ:MYNZ) versus TAT Technologies (NASDAQ:TATT) Financial Contrast

TAT Technologies (NASDAQ:TATT – Get Free Report) and Mainz Biomed (NASDAQ:MYNZ – Get Free Report) are both small-cap industrials companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.

Profitability

This table compares TAT Technologies and Mainz Biomed’s net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for TAT Technologies and Mainz Biomed, as provided by MarketBeat.com.

TAT Technologies presently has a consensus target price of $57.86, indicating a potential upside of 62.81%. Given TAT Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe TAT Technologies is more favorable than Mainz Biomed.

Institutional & Insider Ownership

15.1% of TAT Technologies shares are owned by institutional investors. 8.7% of TAT Technologies shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

TAT Technologies has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.

Valuation & Earnings

This table compares TAT Technologies and Mainz Biomed”s top-line revenue, earnings per share (EPS) and valuation.

TAT Technologies has higher revenue and earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than TAT Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

TAT Technologies beats Mainz Biomed on 13 of the 15 factors compared between the two stocks.

About TAT Technologies

(Get Free Report)

TAT Technologies Ltd., together with its subsidiaries, provides solutions and services to the commercial and military aerospace, and ground defense industries in the United States, Israel, and internationally. The company operates through four segments: Original Equipment Manufacturing (OEM) of Heat Transfer Solutions and Aviation Accessories; Maintenance, Repair, and Overhaul (MRO) Services for Heat Transfer Components and OEM of Heat Transfer Solutions; MRO Services for Aviation Components; and Overhaul and Coating of Jet Engine Components. It designs, develops, and manufactures a range of heat transfer solutions, such as pre-cooler and oil/fuel hydraulic heat exchangers used in mechanical and electronic systems in commercial, military, and business aircraft; environmental control and power electronics cooling systems for use in aircraft and ground applications; and a range of other mechanical aircraft accessories and systems, such as pumps, valves, and turbine power units. The company provides MRO services for heat transfer components, as well as for manufacturing heat transfer solutions; and aviation components. In addition, it engages in the operation of a repair station, which provides heat transfer MRO services for airlines, air cargo carriers, maintenance service centers, and the military; and the overhaul and coating of jet engine components, including turbine vanes and blades, fan blades, variable inlet guide vanes, and afterburner flaps. The company was formerly known as Galagraph Ltd. and changed its name to TAT Technologies Ltd. in May 1992. TAT Technologies Ltd. was founded in 1969 and is headquartered in Netanya, Israel.

About Mainz Biomed

(Get Free Report)

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.